| 8513234 |
HIV integrase inhibitors |
Richard Isaacs, Peter D. Williams, Dai-Shi Su, Shankar Venkatraman, Mark W. Embrey +15 more |
2013-08-20 |
$90,590,000 |
| 7855201 |
Morpholine carboxamide prokineticin receptor antagonists |
Jeffrey Melamed |
2010-12-21 |
$142,113,000 |
| 7452893 |
4-cycloakylaminopyrazolo pyrimidine NMDA/NR2B antagonists |
Steven D. Young, Brian Phillips, Peter M. Munson, Willie Whitter, Nigel J. Liverton +6 more |
2008-11-18 |
$97,411,000 |
| 7259157 |
N-substituted nonaryl-heterocyclo amidyl NMDA/NR2B Antagonists |
Nigel J. Liverton, John W. Butcher, Charles J. McIntyre, Christopher F. Claiborne, David A. Claremon +3 more |
2007-08-21 |
$80,895,000 |
| 7217716 |
N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists |
Christopher F. Claiborne, David A. Claremon, Brian Libby, John W. Butcher, John A. McCauley +4 more |
2007-05-15 |
$75,282,000 |
| 7053089 |
N-substituted nonaryl-heterocyclic NMDA/NR2B antagonists |
Christopher F. Claiborne, John W. Butcher, David A. Claremon, Brian Libby, Nigel J. Liverton +4 more |
2006-05-30 |
$88,964,000 |
| 6632836 |
Carbocyclic potassium channel inhibitors |
Robert K. Baker, Jianming Bao, Jennifer Chee, Maria L. Garcia, Gregory J. Kaczorowski +10 more |
2003-10-14 |
$62,367,000 |
| 6495561 |
2-cyclohexyl imidazopyridine NMDA/NR2B antagonists |
David A. Claremon, Peter M. Munson, John A. McCauley |
2002-12-17 |
$84,823,000 |
| 6489477 |
2-aza-bicyclo[2.2.2]octane NMDA/NR2B antigonists |
David A. Claremon, Peter M. Munson |
2002-12-03 |
$100,921,000 |
| 6476041 |
1,4 substituted piperidinyl NMDA/NR2B antagonists |
David A. Claremon, Peter M. Munson, Janusz Kulagowski, Willie Whitter, Ian Thomas Huscroft |
2002-11-05 |
$137,125,000 |
| 6432976 |
8-aza-bicyclo[3.2.1]octane NMDA/NR2B antagonists |
David A. Claremon, Peter M. Munson, Brian Phillips |
2002-08-13 |
$67,146,000 |
| 6380205 |
2-cyclohexyl quinazoline NMDA/NR2B antagonists |
David A. Claremon, Peter M. Munson, John A. McCauley |
2002-04-30 |
$87,345,000 |
| 6369076 |
5-benzyl-octahydroindole and 6-benzyl-decahydroquinoline NMDA/NR2B antagonists |
David A. Claremon, Peter M. Munson |
2002-04-09 |
$96,283,000 |
| 6303637 |
Heterocyclic potassium channel inhibitors |
Jianming Bao, Andrew Kotliar, Frank Kayser, William H. Parsons, Kathleen M. Rupprecht +3 more |
2001-10-16 |
$170,031,000 |
| 6291499 |
2-cyclohexyl benzimidazole NMDA/NR2B antagonists |
David A. Claremon, Peter M. Munson, John A. McCauley |
2001-09-18 |
$92,079,000 |
| 6194458 |
Benzamide potassium channel inhibitors |
Robert K. Baker, Jianming Bao, Frank Kayser, Andrew Kotliar, William H. Parsons +4 more |
2001-02-27 |
$326,711,000 |
| 5939414 |
Benzodiazepine hydrazide derivatives as inhibitors of HIV integrase |
Ian M. Bell, Daria Hazuda, James P. Guare, Jr., Peter M. Munson, Joseph P. Vacca |
1999-08-17 |
$105,078,000 |
| 5760054 |
Alpha IC adrenergic receptor antagonists |
Joel R. Huff, Hee Yoon Lee, Jennie B. Nerenberg, Ian M. Bell |
1998-06-02 |
$86,758,000 |
| 5756508 |
Muscarine antagonists |
Richard W. Ransom, Pierre Mallorga, Michael F. Sugrue |
1998-05-26 |
$93,595,000 |
| 5691323 |
Muscarine antagonists |
Michael F. Sugrue, Richard W. Ransom, Pierre Mallorga, Ian M. Bell, Anthony M. Smith |
1997-11-25 |
$90,381,000 |
| 5574044 |
Muscarine antagonists |
Michael F. Sugrue, Richard W. Ransom, Pierre Mallorga, Ian M. Bell, Anthony M. Smith |
1996-11-12 |
$119,086,000 |
| 5502060 |
HIV protease inhibitors |
Arun K. Ghosh, Joel R. Huff, Hee Yoon Lee |
1996-03-26 |
$67,991,000 |
| 5192668 |
Synthesis of protease inhibitor |
Laszlo R. Treiber, Lawrence F. Colwell, Jr., Byron H. Arison, Georgette Dezeny, Russell B. Lingham +1 more |
1993-03-09 |
$66,708,000 |
| 4927965 |
N-(N-succinyl-L-leucyl)agmatine, related compounds and use in pharmacology |
Gabriel F. Eilon |
1990-05-22 |
$63,323,000 |
| 4870079 |
Derivatives of 5-methyl-10,11-dihydro-5H-dibenzo[a,d]cyclohepten-5,10-imine |
Susan F. Britcher, Terry A. Lyle, Sandor L. Varga |
1989-09-26 |
$19,280,000 |
